What's in Iovance Biotherapeutics, Inc.'s pipeline?

Iovance Biotherapeutics, Inc. has 7 drugs in our index: 0 marketed, 0 filed, 2 in Phase 3, 2 in Phase 2, 3 in Phase 1.

Which companies overlap with Iovance Biotherapeutics, Inc.'s portfolio?

Top competitors by shared drug class: ASLAN Pharmaceuticals, ATGC Co., Ltd., Addpharma Inc., Ahn-Gook Pharmaceuticals Co.,Ltd, Akeso.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/iovance-biotherapeutics-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Iovance Biotherapeutics, Inc. — Portfolio Competitive Intelligence Brief

Iovance Biotherapeutics, Inc. pipeline: 0 marketed, 0 filed, 2 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 2 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Lifileucel plus Pembrolizumab	Lifileucel plus Pembrolizumab	phase 3	Autologous cell therapy combined with PD-1 inhibitor	PD-1 (pembrolizumab component); tumor-associated antigens (lifileucel component)	Oncology
Pembrolizumab with Optional Crossover Period	Pembrolizumab with Optional Crossover Period	phase 3	PD-1 inhibitor	PD-1	Oncology

Therapeutic area mix

Oncology · 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

ASLAN Pharmaceuticals · 1 shared drug class
ATGC Co., Ltd. · 1 shared drug class
Addpharma Inc. · 1 shared drug class
Ahn-Gook Pharmaceuticals Co.,Ltd · 1 shared drug class
Akeso · 1 shared drug class
Amgen · 1 shared drug class
Asahi Kasei Pharma Corporation · 1 shared drug class
3D Medicines (Sichuan) Co., Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Iovance Biotherapeutics, Inc.:

Cite this brief

Drug Landscape (2026). Iovance Biotherapeutics, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/iovance-biotherapeutics-inc. Accessed 2026-05-16.